Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HRS-4642: The next piece of the puzzle to keep KRAS in check.

Cancer cell - 8 Jul 2024

Flores-Gómez Alejandra A, Drosten Matthias

Abstract excerpt

KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasms
Share to Antineoplastic Agents
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proteasome Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38981436
DOI: 10.1016/j.ccell.2024.06.005

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HRS-4642: The next piece of the puzzle to keep KRAS in check.PMID 38981436Read ↗

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer.Semantic proximity Read ↗

Drugging RAS: Moving Beyond KRASG12C.Semantic proximity Read ↗

The KRASG12D Inhibitor Pipeline Grows.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.Semantic proximity Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

RAS at 40: Update from the RAS Initiative.Semantic proximity Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read ↗

Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.